Biden names Dr. Ashish Jha new Covid response coordinator to succeed Jeff Zients

Biden names Dr. Ashish Jha new Covid response coordinator to succeed Jeff Zients


Dr. Ashish Jha is pictured in Providence, RI on Dec. 3, 2020.

Jonathan Wiggs | Boston Globe | Getty Images

President Joe Biden on Thursday named Dr. Ashish Jha as his new Covid-19 response coordinator to succeed Jeff Zients, who served in the role through the delta and omicron surges.

Jha leads Brown University’s School of Public Health and previously headed Harvard’s Global Health Institute. He is a well-known public commentator on how Americans should respond to health risks in the pandemic.

Jha, in a Twitter post, cautioned that the pandemic is not over and the U.S. needs to prepare for future variants and surges by keeping schools and workplaces safe.

New Covid infections in the U.S. have plunged more than 90% since the peak of an unprecedented omicron surge in January, according to data from Johns Hopkins University. Hospitalizations are down 89% from the omicron peak, according to the Centers for Disease Control and Prevention. However, infections are rising again in major European nations, such as the U.K. and Germany, and China is battling its worst outbreak since 2020.

Zients has led the White House Covid response team for 14 months and has held countless public briefings on the changing state of pandemic. Biden praised Zients’ work in a statement, noting that most adults have become fully vaccinated during his tenure. More than 75% of adults in the U.S. have received two doses of a vaccine, according to CDC data.

“The progress that he and his team have made is stunning and even more important consequential. Lives have been saved,” Biden said in a statement

CNBC Health & Science

Read CNBC’s latest global coverage of the Covid pandemic:



Source

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Health

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale

Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill market. Eli Lilly stock slipped about half a percent this morning, while Novo Nordisk shares surged more than 8% after becoming the first to secure FDA approval for a GLP-1 weight-loss pill. “[Novo] got approval ahead of […]

Read More
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
Health

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk, a landmark decision that health experts […]

Read More
UnitedHealth Group commits to improvements after independent audit, patient backlash
Health

UnitedHealth Group commits to improvements after independent audit, patient backlash

UnitedHealthcare sign is displayed at its office building in Minnetonka, Minnesota, U.S., Dec. 11, 2025. Tim Evans | Reuters UnitedHealth Group on Friday released the first results from a sprawling independent audit of its business practices and committed to a wide range of steps to track and implement improvements in three specific areas. The health-care […]

Read More